Cannabinoid Receptor Antagonists
- Cannabinoid Receptor Antagonists
- Accession Number
Compounds that inhibit or block the activity of CANNABINOID RECEPTORS.
Drug Drug Description Rimonabant For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated... Ibipinabant Ibipinabant has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes. Surinabant Surinabant has been investigated for the treatment of Smoking Cessation. SLV319 Investigated for use/treatment in obesity. WIN 55212-2 WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure. It... Otenabant Otenabant has been investigated for the treatment of Obesity.
- Drugs & Drug Targets
Drug Target Type Rimonabant Cannabinoid receptor 1 target Rimonabant Cytochrome P450 3A4 enzyme Rimonabant G-protein coupled receptor 55 target SLV319 Cannabinoid receptor 1 target WIN 55212-2 Cytochrome P450 3A4 enzyme Otenabant Cannabinoid receptor 1 target